中国临床药理学杂志Issue(7)：568-570,3.DOI:10.13699/j.cnki.1001-6821.2014.07.003
沙格列汀联合门冬胰岛素30注射液治疗老年2型糖尿病的临床研究
Clinical trial of saxagliptin combined with insulin aspart 30 injection in treatment of elderly patients with type 2 diabetes
摘要
Abstract
Objective To study the safety and efficacy of saxagliptin combined with insulin aspart 30 injection ( BIAsp30 ) in the treatment of elderly patients with type 2 diabetes( T2Db).Methods The 84 elderly patients with T2Db mellitus inadequately controlled with oral antidiabetic drugs were randomly divided into 2 groups with 12 weeks of treatment.The patients in the trial group were given oral saxagliptin 5 mg once a day, combined with BIAsp30 insulin injections twice a day.The patients in the control group only were given BIAsp 30 insulin injections twice a day.The items were investigated in two groups after administration.Results After treatment, the fasting blood glucose (FBG), postprandial 2 h b1ood glucose (2hBG), and hemoglobin Alc(HbA1c) were signifi-cantly lower than that before treatment in two groups ( all P <0.05 ) . Compared with the control group , 2hBG level in trial group was signifi-cantly decreased ( P<0.05 ).Dosage of insulin , incidence of hypogly-caemia and body mass index ( BMI ) in trial group were significantly re-duced ( all P<0.05 ).Conclusion Saxagliptin combined with BIAsp 30 was found to be safe and effective to improve the glycaemia control in eld-erly patients with T2 Db , especially the 2 hBG level , and the drugs can reduce the dosage of insulin ,lose weight and decrease the risk of hypo-glycaemia for the T2Db mellitus patients.关键词
老年2型糖尿病/沙格列汀/门冬胰岛素30注射液/糖化血红蛋白/空腹血糖Key words
elderly patient with type 2 diabetes mellitus/saxagliptin/insulin aspart 30 injection/hemoglobin A1 c/fasting blood glucose分类
医药卫生引用本文复制引用
李英,朱红霞,王敏哲..沙格列汀联合门冬胰岛素30注射液治疗老年2型糖尿病的临床研究[J].中国临床药理学杂志,2014,(7):568-570,3.基金项目
新疆医科大学创新基金资助项目 （）
